Research: Pediatric Fatality Secondary to EDTA Chelation

|

Authored by Baxter, AJ, and Krenzelok EP in Clinical Toxicology, Volume 46, Issue , p. 1083-1084, (2008).

Article summary (posted Feb 11, 2009):

Chelation therapy may result in death.

The U.S. Food and Drug Administration does not approve the use of chelation therapy to treat autism. This case study describes a 5-year-old boy with autism who was given chelation therapy. The boy died from a heart attack. This is the second case of a child dying from chelation therapy. The authors conclude that doctors should know that there are two types of EDTA chelation therapies and that one is more dangerous than the other.

Links:

You can access the original abstract and the complete paper is sometimes available for free via Google Scholar (look for entries that say "PDF" or "HTML" on the right side of the page).
autism, case study, chelation, drug, Food and Drug Administration (FDA), therapy
|